In the ever-evolving landscape of cardiovascular research, the WARRIOR trial—short for Women’s Ischemia Trial to Reduce Events in Non-Obstructive CAD—has emerged as a pivotal investigation into how best to treat women with ischemia and no obstructive coronary artery disease (INOCA). … Read More
coronary artery disease
GLAGOV Trial: Evolocumab on CAD Progression
GLAGOV Trial: Effect of Evolocumab on Coronary Disease Progression in Statin-Treated Patients The GLAGOV trial is a double-blind, placebo-controlled, randomized study designed to assess the impact of PCSK9 inhibition with evolocumab on the progression of coronary atherosclerosis in patients already … Read More
EPIC-CAD Trial: Edoxaban in CAD and AF
The EPIC-CAD trial, recently published in The New England Journal of Medicine, evaluated the efficacy and safety of edoxaban monotherapy compared to dual antithrombotic therapy in patients with stable coronary artery disease (CAD) and high-risk atrial fibrillation (AF). This open-label, … Read More
EMPACT-MI: Empagliflozin after MI
Year: 2024 Title: EMPACT-MI Subtitle: Empagliflozin after Acute Myocardial Infarction Type of Trial: A double-blind, randomized, placebo-controlled trial Objective: To assess if the use of empagliflozin in the treatment of acute myocardial infarction (AMI) affects future mortality or heart failure … Read More
OCTOBER Trial: OCT in Complex PCI
The OCTOBER trial, detailed in the New England Journal of Medicine in 2023, was a multicenter, randomized, open-label trial designed to assess the effectiveness of optical coherence tomography (OCT) in guiding percutaneous coronary intervention (PCI) for the treatment of complex … Read More
ISCHEMIA Trial: Invasive or Medical therapy for Stable CAD
2020 ISCHEMIA TRIAL M Initial Invasive or Conservative Strategy for Stable Coronary Disease multicenter, parallel, randomized controlled trial Objective: Tto determine the effect of adding cardiac catheterization (hereafter, angiography) and revascularization when feasible to medical therapy in patients with stable … Read More
ADAPTABLE Trial Summary: Aspirin Dosing in CV Disease
2013 ADAPTABLE TRIAL Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease Open-label, pragmatic design, randomized controlled trial M Objective: To assess whether a strategy of aspirin 325 mg/day would result in a lower risk of death from any cause, hospitalization … Read More
ISCHEMIA-CKD Trial Summary: CAD Management in Advanced CKD
2020 ISCHEMIA-CKD TRIAL Management of coronary disease in patients with advanced kidney disease international, randomized controlled trial Objective: To compare the effectiveness of routine invasive therapy with optimal medical therapy among patients with stable coronary disease & advanced chronic kidney … Read More
POPULAR CABG Trial Summary: Ticagrelor in CABG
2020 POPULAR CABG TRIAL Effect of adding ticagrelor to standard aspirin on saphenous vein graft (SVG) patency in patients undergoing coronary artery bypass grafting double-blind, placebo-controlled, multicenter, randomized controlled trial M Objective: To assess whether ticagrelor added to standard aspirin … Read More